Digital health, diagnostics and medical devices, and the signals that matter for adoption, reimbursement and outcomes.
Page 8 of 8
Jan 6, 2026The launch of the oral Wegovy pill has triggered a swift response from telehealth platforms aiming to capitalize on the growing obesity treatment market by expanding access to this convenient medication deployment option.
TCB Team
Jan 6, 2026With obesity continuing as a widespread health issue, telehealth companies are capitalizing on the convenience and accessibility of the newly approved oral Wegovy pill. The move reflects a growing trend of digital health platforms integrating pharmaceutical therapies for greater patient reach.
TCB TeamMachine learning, predictive models and computational biology: how AI is changing discovery workflows and probability of success.
Drug development, clinical trials and industry dynamics. What changes timelines, risk and competitive positioning.
Gene therapy, CRISPR, synthetic biology and emerging platforms. Separating what is real from what is hype, and what actually translates.
Where capital is flowing and why the tape moves, across funding rounds, M&A, IPOs and market analysis.
FDA actions, approvals, policy shifts and compliance: how the rules change timelines and probability.